Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERGOLOID MESYLATES vs Ergometrine / Methylergonovine
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
Ergometrine and methylergonovine are ergot alkaloids that act as partial agonists at alpha-adrenergic, dopaminergic, and serotonergic (5-HT2) receptors. Their primary uterotonic effect is mediated by stimulation of 5-HT2 receptors in uterine smooth muscle, leading to sustained contractions and vasoconstriction.
Treatment of age-related cognitive decline,Dementia (unlabeled use)
Prevention and treatment of postpartum hemorrhage (FDA approved),Uterine atony (FDA approved),Ovarian hyperstimulation syndrome (off-label),Variceal bleeding (off-label),Migraine headache (off-label)
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
0.2 mg intramuscularly or intravenously, repeated every 2-4 hours as needed, up to 5 doses total. Maximum single dose: 0.5 mg. Maximum total dose: 1 mg.
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
30-120 min (biphasic: initial 10 min, terminal 30-120 min); clinical context: short half-life allows repeated dosing for postpartum hemorrhage but requires monitoring for accumulation
Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect.
Primarily hepatic via CYP3A4; also undergoes first-pass metabolism. Metabolites are excreted in urine and bile.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
Renal (20% unchanged), biliary/fecal (35% as metabolites and parent compound)
Approximately 90% bound to albumin.
85-90% (primarily to albumin and α1-acid glycoprotein)
1.5-2 L/kg, indicating extensive tissue distribution.
0.4-0.6 L/kg; clinical meaning: moderate tissue distribution, consistent with limited extravascular binding
Oral: less than 10% due to extensive first-pass metabolism.
Oral: 20-40% (due to extensive first-pass metabolism); IM: ~80%
Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 m L/min).
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to risk of accumulation and hypertensive effects.
Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% or extend interval. Child-Pugh Class C: avoid use.
Not established; safety and efficacy not determined in pediatric patients.
0.1-0.2 mg intramuscularly or intravenously every 2-4 hours as needed; maximum single dose 0.2 mg. For postpartum hemorrhage, 0.2 mg IM/IV repeated every 2-4 hours, max 5 doses.
Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects.
Use lowest effective dose due to increased sensitivity and higher risk of hypertension and coronary vasospasm; consider 0.1 mg initially and titrate cautiously.
No FDA black box warning.
Concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, protease inhibitors, azole antifungals) may result in acute ergot toxicity (vasospasm, cerebral and peripheral ischemia). Contraindicated in pregnancy for induction of labor due to risk of uterine rupture and fetal harm.
Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism.
May cause hypertension, especially in patients with preeclampsia or hypertension. Use with caution in patients with sepsis, hepatic or renal impairment, coronary artery disease, or peripheral vascular disease. Avoid prolonged use. Monitor uterine tone and bleeding.
Hypersensitivity to ergot alkaloids; severe hypotension; acute or chronic psychosis; concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals).
Pregnancy (except for postpartum hemorrhage), hypertension, preeclampsia, eclampsia, coronary artery disease, peripheral vascular disease, Raynaud's phenomenon, sepsis, hypersensitivity to ergot alkaloids, concurrent use of potent CYP3A4 inhibitors.
Avoid grapefruit juice as it may increase drug levels. Limit caffeine intake as it may exacerbate vasoconstrictive effects. Maintain adequate hydration.
No known food interactions.
Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions.
First trimester: Limited human data; animal studies show embryotoxicity and fetotoxicity at high doses due to uterotonic effects, but no structural malformations. Increased risk of spontaneous abortion from uterine hyperstimulation. Second trimester: Uterotonic effects may cause placental abruption, preterm labor, or fetal hypoxia. Third trimester: Contraindicated due to potent uterotonic activity; can cause uterine tetany, fetal distress, and stillbirth. Avoid during pregnancy unless for postpartum hemorrhage.
Excreted into breast milk; M/P ratio unknown. May suppress prolactin and reduce milk production. Potential for ergotism in neonates (vomiting, diarrhea, convulsions). Contraindicated during breastfeeding.
Ergometrine and methylergonovine are excreted into breast milk in small amounts; M/P ratio estimated at 0.2-0.3. Milk concentrations are low (approximately 1-2% of maternal weight-adjusted dose). The American Academy of Pediatrics considers use compatible with breastfeeding, but may cause ergotism in infants (vomiting, diarrhea, seizures) with prolonged use. Short-term use for postpartum hemorrhage is generally acceptable.
No established safe dose in pregnancy. Avoid use. If absolutely necessary, lowest effective dose and shortest duration, but no specific pharmacokinetic data available to guide adjustments.
No dose adjustment required for pregnancy because drug is contraindicated during pregnancy due to uterotonic effects. In postpartum use (which is the approved indication), no pharmacokinetic changes necessitate dose adjustment; normal adult dosing applies (0.2 mg IM/IV for ergometrine, 0.2 mg IM for methylergonovine).
Ergoloid mesylates are a mixture of dihydrogenated ergot alkaloids historically used for dementia, though efficacy is unproven. Avoid in patients with psychosis, severe bradycardia, or recent MI. Monitor for ergotism symptoms (vasospasm, ischemia). Not recommended due to lack of evidence.
Administer intramuscularly or intravenously (slow push over 1 minute) for uterine atony; avoid in hypertension, preeclampsia, and sepsis. Store ampules protected from light; discard if discolored. Contraindicated in impaired hepatic or renal function.
Take exactly as prescribed; do not double doses if missed.,Report signs of ergotism: cold/blue fingers/toes, muscle pain, tingling or numbness.,Avoid smoking and caffeine as they may worsen vasoconstriction.,May cause dizziness or fainting; avoid driving until you know how the drug affects you.,Do not use with other ergot alkaloids or triptans.
This medication may cause nausea, vomiting, or headache.,Report severe abdominal pain, chest pain, or difficulty breathing immediately.,Avoid driving or operating machinery if dizziness occurs.,Do not use during pregnancy except for postpartum hemorrhage.,Inform your doctor if you have high blood pressure, heart disease, or are breastfeeding.
No interactions on record
"Coadministration of bromocriptine, a dopamine D2 receptor agonist with vasoconstrictive properties, and ergometrine, an ergot alkaloid that acts as a partial agonist at alpha-adrenergic and serotonin receptors, synergistically increases peripheral vasoconstriction. This additive effect can lead to severe hypertension, myocardial ischemia, cerebral vasospasm, and potentially life-threatening ergotism. Patients may present with headache, chest pain, altered mental status, or peripheral ischemia."
"Nylidrin, a beta-adrenergic agonist, and ergometrine, an ergot alkaloid with vasoconstrictive properties, exhibit a synergistic hypertensive effect. By stimulating beta-2 receptors, nylidrin may cause peripheral vasodilation and reflex tachycardia, while ergometrine induces vasoconstriction via alpha-adrenergic and serotonin receptor activation. This opposing mechanism can lead to unopposed vasoconstriction, potentially resulting in severe hypertension, myocardial ischemia, or stroke."
"Simvastatin, a HMG-CoA reductase inhibitor, may increase the serum concentration of ergometrine, an ergot alkaloid used for postpartum hemorrhage, by inhibiting its metabolism via CYP3A4. This can lead to enhanced vasoconstrictive effects of ergometrine, potentially causing severe hypertension, myocardial ischemia, or peripheral vasospasm. Concomitant use poses a risk of ergotism, manifesting as ischemic complications, and should be approached with caution."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERGOLOID MESYLATES vs Ergometrine / Methylergonovine, answered by our medical review team.
ERGOLOID MESYLATES is a Ergot Alkaloid that works by Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.. Ergometrine / Methylergonovine is a Ergot Alkaloid Uterotonic that works by Ergometrine and methylergonovine are ergot alkaloids that act as partial agonists at alpha-adrenergic, dopaminergic, and serotonergic (5-HT2) receptors. Their primary uterotonic effect is mediated by stimulation of 5-HT2 receptors in uterine smooth muscle, leading to sustained contractions and vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERGOLOID MESYLATES and Ergometrine / Methylergonovine depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERGOLOID MESYLATES is: Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.. The standard adult dose of Ergometrine / Methylergonovine is: 0.2 mg intramuscularly or intravenously, repeated every 2-4 hours as needed, up to 5 doses total. Maximum single dose: 0.5 mg. Maximum total dose: 1 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERGOLOID MESYLATES and Ergometrine / Methylergonovine in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERGOLOID MESYLATES is classified as Category A/B. Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. . Ergometrine / Methylergonovine is classified as Category C. First trimester: Limited human data; animal studies show embryotoxicity and fetotoxicity at high doses due to uterotonic effects, but no structural malformations. Increased risk of. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.